GLENMARK
Invest Now
Start SIP in
GLENMARK
Performance
- Low
- ₹1,372
- High
- ₹1,407
- 52 Week Low
- ₹985
- 52 Week High
- ₹1,831
- Open Price₹1,384
- Previous Close₹1,384
- Volume694,501
Investment Returns
- Over 1 Month -10.37%
- Over 3 Month -4.98%
- Over 6 Month -17.55%
- Over 1 Year + 28.95%
Smart Investing Starts Here Start SIP with Glenmark Pharmaceuticals for Steady Growth!
Glenmark Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- -221.7
- PEG Ratio
- -2.8
- Market Cap Cr
- 38,978
- P/B Ratio
- 4.6
- Average True Range
- 50.63
- EPS
- 0
- Dividend Yield
- 0.2
- MACD Signal
- -13.01
- RSI
- 45.09
- MFI
- 59.56
Glenmark Pharmaceuticals Financials
Glenmark Pharmaceuticals Technicals
EMA & SMA
Current Price
₹1,381.20
-3.2
(-0.23%)

-
- Bearish Moving Average 16
-
- Bullish Moving Average 0
- 20 Day
- ₹1,407.17
- 50 Day
- ₹1,427.73
- 100 Day
- ₹1,454.16
- 200 Day
- ₹1,424.15
Resistance and Support
1386.6
- R3 1,435.80
- R2 1,421.20
- R1 1,401.20
- S1 1,366.60
- S2 1,352.00
- S3 1,332.00
Glenmark Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
Date | Purpose | Remarks |
---|---|---|
2025-02-14 | Quarterly Results | |
2024-11-14 | Quarterly Results | |
2024-08-14 | Quarterly Results | |
2024-05-24 | Audited Results & Final Dividend | |
2024-02-14 | Quarterly Results |
Glenmark Pharmaceuticals F&O
About Glenmark Pharmaceuticals
- NSE Symbol
- GLENMARK
- BSE Symbol
- 532296
- Chairman & Managing Director
- Mr. Glenn Saldanha
- ISIN
- INE935A01035
Similar Stocks to Glenmark Pharmaceuticals
Glenmark Pharmaceuticals FAQs
Glenmark Pharmaceuticals share price is ₹1,381 As on 01 May, 2025 | 05:15
The Market Cap of Glenmark Pharmaceuticals is ₹38977.6 Cr As on 01 May, 2025 | 05:15
The P/E ratio of Glenmark Pharmaceuticals is -221.7 As on 01 May, 2025 | 05:15
The PB ratio of Glenmark Pharmaceuticals is 4.6 As on 01 May, 2025 | 05:15
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.